Pembrolizumab Market Size, Share & Industry Analysis, By Product Type (KEYTRUDA IV and KEYTRUDA QLEX / SC Pembrolizumab), By Disease Indication (NSCLC, Melanoma, HNSCC, Urothelial Carcinoma, RCC, TNBC, Gastric/GEJ/Esophageal Cancers, Cervical Cancer, and Others), By Age Group (Pediatric and Adults), By Type (Branded and Biosimilar), By Therapy Setting (Early-stage / Perioperative, Advanced / Metastatic, and Others), By Route of Administration (IV and SC), By End User (Hospitals, Specialty Cancer Clinics, Ambulatory Infusion Centers, and Others), and Regional Forecast, 2026-2034

Last Updated: April 16, 2026 | Format: PDF | Report ID: FBI115937

To get information on various segments, share your queries with us

ATTRIBUTE	DETAILS
Study Period	2021-2034
Base Year	2025
Estimated Year	2026
Forecast Period	2026-2034
Historical Period	2021-2024
Growth Rate	CAGR of 2.74% from 2026 to 2034
Unit	Value (USD Billion)
Segmentation	By Product Type, Disease Indication, Age Group, Type, Therapy Setting, Route of Administration, End User, and Region
By Product Type	KEYTRUDA IV KEYTRUDA QLEX / SC Pembrolizumab
By Disease Indication	NSCLC Melanoma HNSCC Urothelial Carcinoma RCC TNBC Gastric/GEJ/Esophageal Cancers Cervical Cancer Others
By Age Group	Pediatric Others
By Type	Branded Biosimilar
By Therapy Setting	Early-stage / Perioperative Advanced / Metastatic Others
By Route of Administration	IV SC
By End User	Hospitals Specialty Cancer Clinics Ambulatory Infusion Centers Others
By Region	North America (By Product Type, Disease Indication, Age Group, Type, Therapy Setting, Route of Administration, End User, and Country) U.S. Canada Europe (By Product Type, Disease Indication, Age Group, Type, Therapy Setting, Route of Administration, End User, and Country/Sub-region) Germany U.K. France Spain Italy Scandinavia Rest of Europe Asia Pacific (By Product Type, Disease Indication, Age Group, Type, Therapy Setting, Route of Administration, End User, and Country/Sub-region) China Japan India Australia Southeast Asia Rest of Asia Pacific Latin America (By Product Type, Disease Indication, Age Group, Type, Therapy Setting, Route of Administration, End User, and Country/Sub-region) Brazil Mexico Rest of Latin America Middle East & Africa (By Product Type, Disease Indication, Age Group, Type, Therapy Setting, Route of Administration, End User, and Country/Sub-region) GCC South Africa Rest of the Middle East & Africa